Most Read Articles
Stephen Padilla, 3 days ago
Treatment with oral thrombopoietin receptor agonist eltrombopag leads to similar platelet counts in patients with chronic immune thrombocytopaenia (cITP) and persistent (per)ITP, according to the results of phase III (EXTEND) and IV studies presented at the 23rd Congress of the European Hematology Association (EHA 2018) held in Stockholm, Sweden.
Pearl Toh, 6 days ago
Lonely people were twice as likely to die from any cause than people who did not feel lonely, according to a study based on a national survey presented at the recent EuroHeartCare 2018 in Dublin, Ireland. Also, loneliness is associated with poorer patient-reported outcomes in terms of mental and physical health in patients with heart disease.
Jairia Dela Cruz, 3 days ago
A treatment regimen combining daratumumab plus bortezomib, melphalan and prednisone markedly extends progression-free survival in patients with multiple myeloma, inducing deep responses and demonstrating acceptable tolerability regardless of baseline renal function, according to the results of the phase III ALCYONE study.
Yesterday
Segmentectomy and lobectomy confer similar overall survival (OS) and lung cancer-specific survival (LCSS) among patients with primary nonsmall cell lung cancer (NSCLC) of ≤20 mm without lymph node or distant metastasis, a recent study has shown.

Medications alone may not help smokers quit

Pearl Toh
10 Jan 2018

A study finds no evidence that using pharmaceutical aids alone for smoking cessation helps improve the chances of successful quitting, despite promising results in previous randomized trials and routine prescription of such drugs to help quit smoking.

“Thirty four percent of people who are trying to quit smoking use pharmaceutical aids and yet most are not successful,” said study principal investigator Professor John Pierce of UC San Diego School of Medicine and Moores Cancer Center in La Jolla, California, US.

“The results of randomized trials that tested these interventional drugs showed the promise of doubling cessation rates, but that has not translated into the real world,” he noted, suggesting that this could be due to confounding –individual factors that make quitting difficult may also be associated with the use of pharmaceutical aid. “For instance, heavier smokers are more likely to use a cessation aid and also less likely to successfully quit.”

To avoid confounding bias, Pierce and co-authors applied propensity score matching to users and nonusers of pharmacological aids in the TUS-CPS*, taking into account 12 potential confounders: sex, age, race-ethnicity, education, smoking intensity, previous quit history, nicotine dependence, self-efficacy to quit, use of cessation aid, smoke-free homes, and survey year. A total of 2,129 adult smokers attempting to quit in two longitudinal studies conducted about one decade apart were included. [J Natl Cancer Inst 2017;doi:10.1093/jnci/djx240]

At 1 year follow-up, respondents who used pharmaceutical aids for smoking cessation were no more likely than nonusers to quit and abstained from smoking for ≥30 days (adjusted risk difference [aRD], 0.01, 95 percent confidence interval [CI], -0.03 to 0.05).  

Specifically, no association was found between the use of varenicline (aRD, 0.01, 95 percent CI, -0.07 to 0.11), bupropion (aRD, 0.02, 95 percent CI, -0.04 to 0.09), or nicotine replacement (aRD, 0.01, 95 percent CI, -0.03 to 0.06) and the likelihood of smoking abstinence for ≥30 days at 1 year follow-up.

According to the researchers, use of intensive behavioural counselling with pharmaceutical aids may have enhanced the success rates of smoking cessation in recent large clinical trials, as smoking cessation counselling has been known to be an effective intervention itself. [Lancet 2016;387:2507-2520; JAMA 2016;315:371-379]

“These results suggest a need for reconsidering how cessation assistance is provided at the population level, as the simple provision of pharmaceutical aids to smokers does not appear to be an effective way to increase the proportion who successfully quit for the long term,” they added.

“Smokers who are committed to quitting and want to use a pharmaceutical aid should also enrol in a program that could help them track their progress and support them in their attempt,” said lead author Dr Eric Leas of Stanford University School of Medicine in Stanford, California, US.

“If the products were approved with counselling we may have better success rates. As it is, less than 2 percent of smokers who use a pharmaceutical aid are using any behavioural counselling. In both of these longitudinal studies, this was a recipe for relapse to smoking,” Pierce pointed out. 

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Stephen Padilla, 3 days ago
Treatment with oral thrombopoietin receptor agonist eltrombopag leads to similar platelet counts in patients with chronic immune thrombocytopaenia (cITP) and persistent (per)ITP, according to the results of phase III (EXTEND) and IV studies presented at the 23rd Congress of the European Hematology Association (EHA 2018) held in Stockholm, Sweden.
Pearl Toh, 6 days ago
Lonely people were twice as likely to die from any cause than people who did not feel lonely, according to a study based on a national survey presented at the recent EuroHeartCare 2018 in Dublin, Ireland. Also, loneliness is associated with poorer patient-reported outcomes in terms of mental and physical health in patients with heart disease.
Jairia Dela Cruz, 3 days ago
A treatment regimen combining daratumumab plus bortezomib, melphalan and prednisone markedly extends progression-free survival in patients with multiple myeloma, inducing deep responses and demonstrating acceptable tolerability regardless of baseline renal function, according to the results of the phase III ALCYONE study.
Yesterday
Segmentectomy and lobectomy confer similar overall survival (OS) and lung cancer-specific survival (LCSS) among patients with primary nonsmall cell lung cancer (NSCLC) of ≤20 mm without lymph node or distant metastasis, a recent study has shown.